MeiraGTx Holdings plc (NASDAQ: MGTX) announced the pricing of an underwritten offering of 11,111,111 ordinary shares at $9.00 per share. The clinical-stage genetic medicines company expects gross proceeds of approximately $100 million before deducting underwriting discounts, commissions and offering expenses.

The company stated that net proceeds from the offering, combined with existing cash and cash equivalents, will fund operating expenses and capital expenditure requirements into the second half of 2028. This includes potential commercial launches of bota-vec for X-linked retinitis pigmentosa treatment and AAV-hAQP1 for radiation-induced xerostomia treatment, if approved.

BofA Securities and Goldman Sachs & Co. LLC serve as joint book-running managers, while Raymond James acts as co-manager for the offering. The offering is expected to close on or about April 17, 2026, subject to customary closing conditions.

MeiraGTx is offering the shares under an effective shelf registration statement on Form S-3 filed with the Securities and Exchange Commission on December 21, 2023, and declared effective on December 29, 2023.

The information is based on a company press release statement.